Report: Dendreon looking for buyer

Share this article:

Dendreon's continued slump appears to have forced its hand: Bloomberg reported Monday that the drugmaker, known for its prostate cancer med Provenge, has asked JPMorgan Chase to help it find a buyer.

Dendreon's financial forecasts have been dim: the company managed to narrow its losses during the second quarter, but said in August that it would not be able to hit its 2013 sales target, despite proof that potential patients were responding to its television ads.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Social media perceived as clinical trial risk

The Wall Street Journal reports that patients are sharing a plethora of information about their clinical trial experiences, from how to get picked, to how to figure out who is in a control group.

Cancer PSA features scientists

Stand Up To Cancer is kicking off a PSA that features Grammy-winner Jennifer Hudson and a Genentech scientist.

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.